Hormone replacement therapy in women with past history of endometriosis.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic review methodology
PubMed 17000581 · doi:10.1080/13697130600868711
What was done
Narrative review examining clinical evidence and considerations regarding the risks (recurrence, malignant transformation) and benefits of hormone replacement therapy (HRT) in women rendered estrogen-deficient following treatment for endometriosis.
What was found
The abstract reports no numerical data or statistical estimates. It notes that HRT is associated with an increased, undefined risk of endometriosis recurrence, especially in severe cases, obese patients, and with unopposed estrogen. Delaying HRT initiation after pelvic clearance offered no benefit. Continuous combined preparations or tibolone appeared to be the optimum choice for symptom relief and bone protection.
Why it matters
This review synthesizes clinical rationales for balancing menopausal symptom management against recurrence risk in young surgically menopausal patients with a history of endometriosis.
Limits
Narrative review design with no systematic literature search, meta-analytic pooling, or sample size metrics reported in the abstract. Evidence base is explicitly noted to be sparse and recurrence risk remains unquantified.
Cited by
- supports Postmenopausal estrogen replacement therapy without progesterone can reactivate residual endometriotic implants in patients with a history of endometriosis even after hysterectomy.